Compare Linde PLC (LIN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Linde PLC trades at $484.5 (market cap $226.12B), while State Street SPDR S&P Biotech ETF trades at $158.98. The key difference: Linde PLC pays a 1.3% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Linde PLC nearer its low. Which is the better fit depends on your goals.
| LIN | XBI | |
|---|---|---|
Market Cap | $226.12B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $546.64 | $164.28 |
52-Week Low | $389.38 | $86.92 |
Enterprise Value | $249.24B | — |
Dividend Yield | 1.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $492.46, up 0.51% on the day, with a bearish technical signal but strong fundamentals. The company reported consistent earnings beats, with Q2 2026 EPS of $4.50 exceeding the $4.49 estimate (Zacks Investment Research, 2026-05-01). Revenue growth is steady, and profitability remains robust with a 20.43% net income margin. Analyst sentiment is overwhelmingly positive, with a consensus price target of $553.60.
The outlook for LIN is favorable due to its operational strength and dividend growth, though valuation multiples are elevated. Key risks include rising debt levels and macroeconomic pressures on industrial demand. The stock offers a compelling opportunity for long-term investors seeking quality industrial exposure, but near-term technical weakness may present entry points.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
